Y Intercept Hong Kong Ltd Acquires 63,241 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Y Intercept Hong Kong Ltd lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 48.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,387 shares of the company's stock after buying an additional 63,241 shares during the period. Y Intercept Hong Kong Ltd's holdings in Teva Pharmaceutical Industries were worth $2,972,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Financial Sense Advisors Inc. raised its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after acquiring an additional 157,421 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in Teva Pharmaceutical Industries by 12.2% during the 1st quarter. Allianz Asset Management GmbH now owns 678,992 shares of the company's stock valued at $10,436,000 after buying an additional 73,601 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in Teva Pharmaceutical Industries by 10.8% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 1,894,100 shares of the company's stock valued at $29,112,000 after purchasing an additional 184,100 shares during the last quarter. Kestra Private Wealth Services LLC raised its holdings in shares of Teva Pharmaceutical Industries by 6.6% during the 1st quarter. Kestra Private Wealth Services LLC now owns 33,598 shares of the company's stock valued at $516,000 after buying an additional 2,072 shares in the last quarter. Finally, Carnegie Lake Advisors LLC grew its position in Teva Pharmaceutical Industries by 23.8% during the 1st quarter. Carnegie Lake Advisors LLC now owns 85,350 shares of the company's stock worth $1,312,000 after acquiring an additional 16,400 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $24.71.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Down 0.1%

Teva Pharmaceutical Industries stock opened at $16.30 on Wednesday. The stock has a 50-day moving average price of $16.98 and a 200 day moving average price of $16.87. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The company has a market capitalization of $18.69 billion, a price-to-earnings ratio of -14.17, a price-to-earnings-growth ratio of 0.96 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same period last year, the business earned $0.48 earnings per share. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% on a year-over-year basis. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.